Cardiometabolic & kidneyCohort study
Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients
- Retrospective cohort study
- territory-wide
- target trial emulation
Authors' conclusion
New-onset UTI was associated with an increased risk of cardiovascular and renal events in patients with T2DM prescribed SGLT2 inhibitors. Discontinuing SGLT2 inhibitors after a UTI was linked to a higher risk of cardiovascular and renal outcomes but was not associated with fewer recurrent UTI.
Study context
- Population
- Patients with T2DM prescribed SGLT2 inhibitors, January 2015 to June 2022
- Participants
- 61,606 patients
- Exposure
- Incident urinary tract infection (UTI) vs no UTI; SGLT2 inhibitor discontinuation vs continuation after UTI
- UTIn = 3,921
- Outcome
- CV composite (HF hospitalization, stroke, MI or all-cause mortality) and renal composite (50% eGFR decline, end-stage renal failure or all-cause mortality)
Main finding
As reported in the abstract
Hazard ratio (95% CI)
UTI vs No UTICV composite
3.18(2.88–3.51)
UTI vs No UTIrenal composite
2.51(2.32–2.72)
Discontinuation vs Continued useCV composite
1.35(1.20–1.53)
Discontinuation vs Continued userenal composite
1.35(1.21–1.51)
- Discontinued SGLT2 inhibitors after a UTI
- 32.31%
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Recurrent UTI | 0.96 (0.22–4.29) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. Eur Heart J. Published 17 October 2025. doi:10.1093/eurheartj/ehaf788
Summarised from the published abstract; every number is checked against it